ERBB4 and non-small cell lung carcinoma: The study of two immunotherapy cohorts with clinical and mutational data (Rizvi et al. 2018; Samstein et al. 2019) has been conducted to clarify the relationship between ERBB4 mutations and the prognosis of NSCLC patients receiving ICIs treatment.